Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report)’s stock price dropped 0.6% on Wednesday . The company traded as low as $1.7240 and last traded at $1.78. Approximately 84,121 shares were traded during trading, a decline of 92% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.79.
Virios Therapeutics Trading Down 2.3%
The stock has a market capitalization of $32.16 million, a P/E ratio of -6.19 and a beta of 1.58. The business has a 50-day moving average price of $1.92 and a two-hundred day moving average price of $3.40.
About Virios Therapeutics
Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.
Read More
- Five stocks we like better than Virios Therapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
